64x Bio
YC S18 ↗San Francisco, US · Founded 2017 · 25 employees · 6 known investors
64x develops infrastructure and manufacturing systems for next-generation medicines, focusing on genetic engineering, cell line development, and computational biology to enable scalability of advanced therapies.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesGene TherapyMachine Learningin /64xbio@64xbioycombinator.com ↗
Founders & leadership· Y Combinator alumni (S18)
LR
Lexi Rovnerin𝕏Co-founder & CEO
Investors · 6
In the news
- 64x Bio Launches LV Apex Suite, Expanding Its CellMap-Driven VectorSelect Platform Into Lentiviral Vector Productionbusinesswire.com · 2026
- 64x Bio Launches AAV Apex Suite to Power the Next Generation of Gene Therapy Manufacturingbusinesswire.com · 2025
- Pitch Deck: 64x Bio Raises $55 Million for Cell, Gene Therapy Tools. - Business Insiderbusinessinsider.com · 2022
- 64x Bio Raises $55M To Advance Gene Therapy Platformnews.crunchbase.com · 2022
- 64x Bio Raises $55 Million Series A Financing to Advance Cell Line Engineering Platform for Gene Therapy Manufacturing - BioSpacebiospace.com · 2022